Taking on heart failure, saving lives.
Heart failure prevalence is in excess of 22 million cases worldwide, with 2 million new cases a year. In the US, 670,000 new cases of heart failure are diagnosed each year, affecting 2% of the US population, accounting for 34% of cardiovascular-related deaths, and 1-2% (~$40B) of all health care expenditures.
Our mission is to use ion channel-targeted therapeutics to rescue and reverse the progression of heart failure.
The TRPV1 ion channel controls heart failure progression at the molecular level. We have figured out a way to safely suppress its activity. We have shown conclusively, in animal studies, the this approach not only stops heart failure in its tracks but can reverse the damage.
This is unprecedented, and we have convened a world-class team to place new TRPV1-targeted therapies for heart failure into the hands of physicians and patients worldwide.
“Someone dies of heart failure every 38 seconds”
— American Heart Association